Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

The biological potential hidden in inclusion bodies

  • Gifre-Renom, Laia
  • Seras-Franzoso, Joaquin
  • Rafael, Diana
  • Andrade, Fernanda
  • Cano-Garrido, Olivia
  • Martinez-Trucharte, Francesc
  • Ugarte-Berzal, Estefania
  • Martens, Erik
  • Boon, Lise
  • Villaverde, Antonio
  • Opdenakker, Ghislain
  • Schwartz, Simó Jr.
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Inclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. Nevertheless, IBs have been, so far, exclusively sifted by their biological activity in vitro to be considered in further protein-based treatments in vivo. Matrix metalloproteinase-9 (MMP-9) protein, which has an important role facilitating the migration of immune cells, was used as model protein. The MMP-9 IBs were compared with their soluble counterpart and with MMP-9 encapsulated in polymeric-based micelles (PM) through ionic and covalent binding. The soluble MMP-9 and the MMP-9-ionic PM showed the highest activity values in vitro. IBs showed the lowest activity values in vitro, but the specific activity evolution in 50% bovine serum at room temperature proved that they were the most stable format. The data obtained with the use of an air-pouch mouse model showed that MMP-9 IBs presented the highest in vivo activity compared to the soluble MMP-9, which was associated only to a low and a transitory peak of activity. These results demonstrated that the in vivo performance is the addition of many parameters that did not always correlate with the in vitro behavior of the protein of interest, becoming especially relevant at evaluating the potential of IBs as a protein-based nanomaterial for therapeutic purposes, info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Potential of MMP-9 based nanoparticles at optimizing the cow dry period: pulling apart the effects of MMP-9 and nanoparticles

  • Gifre-Renom, L.
  • Carratalá, J. V.
  • Parés, S.
  • Sánchez-García, L.
  • Ferrer-Miralles, N.
  • Villaverde, A.
  • Bach, A.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
The cow dry period is a non-milking interval where the mammary gland involutes and regenerates to guarantee an optimal milk production in the subsequent lactation. Important bottlenecks such as the high risk of intramammary infections complicate the process. Antibiotics have been routinely used as a preventive treatment but the concerns about potential antibiotic resistance open a new scenario in which alternative strategies have to be developed. Matrix metalloproteinase-9 (MMP-9) is an enzyme able to degrade the extracellular matrix, triggering the involution and immune function of cow mammary gland. We have studied the infusion into the mammary gland of MMP-9 inclusion bodies as protein-based nanoparticles, demonstrating that 1.2 mg of MMP-9 enhanced the involution and immune function of the cow mammary gland. However, the comparison of the efects triggered by the administration of an active and an inactive form of MMP-9 led to conclude that the response observed in the bovine mammary gland was mainly due to the protein format but not to the biological activity of the MMP-9 embedded in the inclusion body. This study provides relevant information on the future use of protein inclusion bodies in cow mammary gland and the role of MMP-9 at dry-of., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Short communication: Recombinant mammary serum amyloid A3 as a potential strategy for preventing intramammary infections in dairy cows at dryoff

  • Parés, Sílvia
  • Fàbregas, Francesc
  • Bach, Àlex
  • Garcia-Fruitos, Elena
  • de Prado, Ana
  • Alomar, Oscar
Mammary serum amyloid A3 (M-SAA3) has shown potential in stimulating innate immunity during intramammary infections, at calving and at dryoff. In this study, we produced recombinant caprine M-SAA3 to test its ability to reduce intramammary infections with Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, and Escherichia coli, which are all common mastitis-producing pathogens. Recombinant production of M-SAA3 (followed by lipopolysaccharide removal to avoid lipopolysaccharide-nonspecific stimulation of the immune system) was successfully achieved. Mammary serum amyloid A3 stimulated the expression of IL-8 in a dose-dependent manner in primary mammary cultures. Although a direct killing effect on Staph. aureus by M-SAA3 was not detected, this acute phase protein was able to reduce Staph. aureus, Strep. uberis, and Strep. dysgalactiae infections by up to 50% and induced a reduction in E. coli counts of 67%. In general, the best concentration of caprine M-SAA3 for inhibiting infections was the lowest concentration tested (10 μg/mL), although higher concentrations (up to 160 μg/mL) increased its antimicrobial potential against some pathogens., info:eu-repo/semantics/acceptedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Recombinant protein-based nanoparticles: Elucidating their inflammatory effects in vivo and their potential as a new therapeutic format

  • Gifre-Renom, Laia
  • Ugarte-Berzal, Estefania
  • Martens, Erik
  • Boon, Lise
  • Cano-Garrido, Olivia
  • Martínez-Núñez, Esther
  • Luque, Teresa
  • Roca-Pinilla, Ramon
  • Conchillo-Solé, Òscar
  • Ferrer-Miralles, Neus
  • Villaverde, Antonio
  • Opdenakker, Ghislain
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Bacterial inclusion bodies (IBs) are protein-based nanoparticles of a few hundred nanometers formed during recombinant protein production processes in different bacterial hosts. IBs contain active protein in a mechanically stable nanostructured format that has been broadly characterized, showing promising potential in different fields such as tissue engineering, protein replacement therapies, cancer, and biotechnology. For immunomodulatory purposes, however, the interference of the format immunogenic properties—intrinsic to IBs—with the specific effects of the therapeutic protein is still an uncovered gap. For that, active and inactive forms of the catalytic domain of a matrix metalloproteinase-9 (MMP-9 and mutMMP-9, respectively) have been produced as IBs and compared with the soluble form for dermal inflammatory effects in mmp9 knock-out mice. After protein injections in air-pouches in the mouse model, MMP-9 IBs induce local neutrophil recruitment and increase pro-inflammatory chemokine levels, lasting for at least two days, whereas the effects triggered by the soluble MMP-9 format fade out after 3 h. Interestingly, the IB intrinsic effects (mutMMP-9 IBs) do not last more than 24 h. Therefore, it may be concluded that IBs could be used for the delivery of therapeutic proteins, such as immunomodulating proteins while preserving their stability in the specific tissue and without triggering important unspecific inflammatory responses due to the protein format., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes

  • Cano‑Garrido, Olivia
  • Seras‑Franzoso, Joaquin
  • Garcia-Fruitos, Elena
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram‑positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Short communication: Recombinant mammary serum amyloid A3 as a potential strategy for preventing intramammary infections in dairy cows at dryoff

  • Parés, Sílvia
  • Fàbregas, Francesc
  • Bach, Àlex
  • Garcia-Fruitos, Elena
  • de Prado, Ana
  • Alomar, Oscar
Mammary serum amyloid A3 (M-SAA3) has shown potential in stimulating innate immunity during intramammary infections, at calving and at dryoff. In this study, we produced recombinant caprine M-SAA3 to test its ability to reduce intramammary infections with Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, and Escherichia coli, which are all common mastitis-producing pathogens. Recombinant production of M-SAA3 (followed by lipopolysaccharide removal to avoid lipopolysaccharide-nonspecific stimulation of the immune system) was successfully achieved. Mammary serum amyloid A3 stimulated the expression of IL-8 in a dose-dependent manner in primary mammary cultures. Although a direct killing effect on Staph. aureus by M-SAA3 was not detected, this acute phase protein was able to reduce Staph. aureus, Strep. uberis, and Strep. dysgalactiae infections by up to 50% and induced a reduction in E. coli counts of 67%. In general, the best concentration of caprine M-SAA3 for inhibiting infections was the lowest concentration tested (10 μg/mL), although higher concentrations (up to 160 μg/mL) increased its antimicrobial potential against some pathogens., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes

  • Cano‑Garrido, Olivia
  • Seras‑Franzoso, Joaquin
  • Garcia-Fruitos, Elena
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram‑positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The biological potential hidden in inclusion bodies

  • Gifre-Renom, Laia
  • Seras-Franzoso, Joaquin
  • Rafael, Diana
  • Andrade, Fernanda
  • Cano-Garrido, Olivia
  • Martinez-Trucharte, Francesc
  • Ugarte-Berzal, Estefania
  • Martens, Erik
  • Boon, Lise
  • Villaverde, Antonio
  • Opdenakker, Ghislain
  • Schwartz, Simó Jr.
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Inclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. Nevertheless, IBs have been, so far, exclusively sifted by their biological activity in vitro to be considered in further protein-based treatments in vivo. Matrix metalloproteinase-9 (MMP-9) protein, which has an important role facilitating the migration of immune cells, was used as model protein. The MMP-9 IBs were compared with their soluble counterpart and with MMP-9 encapsulated in polymeric-based micelles (PM) through ionic and covalent binding. The soluble MMP-9 and the MMP-9-ionic PM showed the highest activity values in vitro. IBs showed the lowest activity values in vitro, but the specific activity evolution in 50% bovine serum at room temperature proved that they were the most stable format. The data obtained with the use of an air-pouch mouse model showed that MMP-9 IBs presented the highest in vivo activity compared to the soluble MMP-9, which was associated only to a low and a transitory peak of activity. These results demonstrated that the in vivo performance is the addition of many parameters that did not always correlate with the in vitro behavior of the protein of interest, becoming especially relevant at evaluating the potential of IBs as a protein-based nanomaterial for therapeutic purposes, info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Recombinant protein-based nanoparticles: Elucidating their inflammatory effects in vivo and their potential as a new therapeutic format

  • Gifre-Renom, Laia
  • Ugarte-Berzal, Estefania
  • Martens, Erik
  • Boon, Lise
  • Cano-Garrido, Olivia
  • Martínez-Núñez, Esther
  • Luque, Teresa
  • Roca-Pinilla, Ramon
  • Conchillo-Solé, Òscar
  • Ferrer-Miralles, Neus
  • Villaverde, Antonio
  • Opdenakker, Ghislain
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Bacterial inclusion bodies (IBs) are protein-based nanoparticles of a few hundred nanometers formed during recombinant protein production processes in different bacterial hosts. IBs contain active protein in a mechanically stable nanostructured format that has been broadly characterized, showing promising potential in different fields such as tissue engineering, protein replacement therapies, cancer, and biotechnology. For immunomodulatory purposes, however, the interference of the format immunogenic properties—intrinsic to IBs—with the specific effects of the therapeutic protein is still an uncovered gap. For that, active and inactive forms of the catalytic domain of a matrix metalloproteinase-9 (MMP-9 and mutMMP-9, respectively) have been produced as IBs and compared with the soluble form for dermal inflammatory effects in mmp9 knock-out mice. After protein injections in air-pouches in the mouse model, MMP-9 IBs induce local neutrophil recruitment and increase pro-inflammatory chemokine levels, lasting for at least two days, whereas the effects triggered by the soluble MMP-9 format fade out after 3 h. Interestingly, the IB intrinsic effects (mutMMP-9 IBs) do not last more than 24 h. Therefore, it may be concluded that IBs could be used for the delivery of therapeutic proteins, such as immunomodulating proteins while preserving their stability in the specific tissue and without triggering important unspecific inflammatory responses due to the protein format., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Potential of MMP-9 based nanoparticles at optimizing the cow dry period: pulling apart the effects of MMP-9 and nanoparticles

  • Gifre-Renom, L.
  • Carratalá, J. V.
  • Parés, S.
  • Sánchez-García, L.
  • Ferrer-Miralles, N.
  • Villaverde, A.
  • Bach, A.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
The cow dry period is a non-milking interval where the mammary gland involutes and regenerates to guarantee an optimal milk production in the subsequent lactation. Important bottlenecks such as the high risk of intramammary infections complicate the process. Antibiotics have been routinely used as a preventive treatment but the concerns about potential antibiotic resistance open a new scenario in which alternative strategies have to be developed. Matrix metalloproteinase-9 (MMP-9) is an enzyme able to degrade the extracellular matrix, triggering the involution and immune function of cow mammary gland. We have studied the infusion into the mammary gland of MMP-9 inclusion bodies as protein-based nanoparticles, demonstrating that 1.2 mg of MMP-9 enhanced the involution and immune function of the cow mammary gland. However, the comparison of the efects triggered by the administration of an active and an inactive form of MMP-9 led to conclude that the response observed in the bovine mammary gland was mainly due to the protein format but not to the biological activity of the MMP-9 embedded in the inclusion body. This study provides relevant information on the future use of protein inclusion bodies in cow mammary gland and the role of MMP-9 at dry-of., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Production of functional inclusion bodies in endotoxin-free Escherichia coli

  • Rueda, Fabián
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Mamat, Uwe
  • Wilke, Kathleen
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Villaverde, Antonio|||0000-0002-2615-4521
Escherichia coli is the workhorse for gene cloning and production of soluble recombinant proteins in both biotechnological and biomedical industries. The bacterium is also a good producer of several classes of protein-based self-assembling materials such as inclusion bodies (IBs). Apart from being a relatively pure source of protein for in vitro refolding, IBs are under exploration as functional, protein-releasing materials in regenerative medicine and protein replacement therapies. Endotoxin removal is a critical step for downstream applications of therapeutic proteins. The same holds true for IBs as they are often highly contaminated with cell-wall components of the host cells. Here, we have investigated the production of IBs in a recently developed endotoxin-free E. coli strain. The characterization of IBs revealed this mutant as a very useful cell factory for the production of functional endotoxin-free IBs that are suitable for the use at biological interfaces without inducing endotoxic responses in human immune cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Expanding the recombinant protein quality in Lactococcus lactis

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Rueda, Fabián L.
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Ruiz-Ávila, Luis
  • Bosser, Ramon
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
Background: Escherichia coli has been a main host for the production of recombinant proteins of biomedical interest, but conformational stress responses impose severe bottlenecks that impair the production of soluble, proteolytically stable versions of many protein species. In this context, emerging Generally Recognized As Safe (GRAS) bacterial hosts provide alternatives as cell factories for recombinant protein production, in which limitations associated to the use of Gram-negative microorganisms might result minimized. Among them, Lactic Acid Bacteria and specially Lactococcus lactis are Gram-positive GRAS organisms in which recombinant protein solubility is generically higher and downstream facilitated, when compared to E. coli. However, deep analyses of recombinant protein quality in this system are still required to completely evaluate its performance and potential for improvement. - Results : we have explored here the conformational quality (through specific fluorescence emission) and solubility of an aggregation-prone GFP variant (VP1GFP) produced in L. lactis. In this context, our results show that parameters such as production time, culture conditions and growth temperature have a dramatic impact not only on protein yield, but also on protein solubility and conformational quality, that are particularly favored under fermentative metabolism. - Conclusions: metabolic regime and cultivation temperature greatly influence solubility and conformational quality of an aggregation-prone protein in L. lactis. Specifically, the present study proves that anaerobic growth is the optimal condition for recombinant protein production purposes. Besides, growth temperature plays an important role regulating both protein solubility and conformational quality. Additionally, our results also prove the great versatility for the manipulation of this bacterial system regarding the improvement of functionality, yield and quality of recombinant proteins in this species. These findings not only confirm L. lactis as an excellent producer of recombinant proteins but also reveal room for significant improvement by the exploitation of external protein quality modulators.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional protein-based nanomaterial produced in GRAS microorganism, a new platform for biotechnology

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Parés, Sílvia
  • Giro Paradell, Irene
  • Tatkiewicz, Witold I.|||0000-0003-1349-2174
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Natalello, Antonino|||0000-0002-1489-272X
  • Cubarsi, Rafael
  • Veciana i Miró, Jaume|||0000-0003-1023-9923
  • Bach, Àlex|||0000-0001-6804-2002
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Arís i Giralt, Anna|||0000-0001-7830-888X
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
Inclusion bodies (IBs) are protein-based nanoparticles formed in Escherichia coli through stereospecific aggregation processes during the overexpression of recombinant proteins. In the last years, it has been shown that IBs can be used as nanostructured biomaterials to stimulate mammalian cell attachment, proliferation, and differentiation. In addition, these nanoparticles have also been explored as natural delivery systems for protein replacement therapies. Although the production of these protein-based nanomaterials in E. coli is economically viable, important safety concerns related to the presence of endotoxins in the products derived from this microorganism need to be addressed. Lactic acid bacteria (LAB) are a group of food-grade microorganisms that have been classified as safe by biologically regulatory agencies. In this context, we have demonstrated herein, for the first time, the production of fully functional, IB-like protein nanoparticles in LAB. These nanoparticles have been fully characterized using a wide range of techniques, including field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, zymography, cytometry, confocal microscopy, and wettability and cell coverage measurements. Our results allow us to conclude that these materials share the main physico-chemical characteristics with IBs from E. coli and moreover are devoid of any harmful endotoxin contaminant. These findings reveal a new platform for the production of protein-based safe products with high pharmaceutical interest.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanostructured recombinant cytokines, A highly stable alternative to short-lived prophylactics

  • Torrealba, Debora
  • Parra, David|||0000-0002-3634-7087
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Vallejos Vidal, Eva Carolina|||0000-0002-3091-2700
  • Yero, Daniel|||0000-0002-6234-4082
  • Gibert, Isidre|||0000-0003-1442-2258
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Roher Armentia, Nerea|||0000-0002-6659-4038
Cytokines have been widely used as adjuvants and therapeutic agents in treatments of human diseases. Despite their recognized potential as drugs, the medical use of cytokines has considerable drawbacks, mainly related to their low stability and short half-life. Such intrinsic limitations imply the administration of high doses, often prompting toxicity, undesirable side effects and greater production costs. Here, we describe a new category of mechanically stable nanostructured cytokines (TNFα and CCL4/MIP-1β) that resist harsh physicochemical conditions in vitro (pH and temperature), while maintaining functionality. These bio-functional materials are produced in recombinant cell factories through cost-effective and fully scalable processes. Notably, we demonstrate their prophylactic potential in vivo showing they protect zebrafish from a lethal infection by Pseudomonas aeruginosa.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lactic acid bacteria, reviewing the potential of a promising delivery live vector for biomedical purposes

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram-positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant protein-based nanoparticles, elucidating their inflammatory effects in vivo and their potential as a new therapeutic format

  • Gifre-Renom, Laia|||0000-0002-2115-2033
  • Ugarte-Berzal, Estefanía
  • Martens, Erik|||0000-0002-7947-6567
  • Boon, Lise
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Martínez-Núñez, Esther
  • Luque, Teresa
  • Roca Pinilla, Ramon
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Opdenakker, Ghislain
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
Bacterial inclusion bodies (IBs) are protein-based nanoparticles of a few hundred nanometers formed during recombinant protein production processes in different bacterial hosts. IBs contain active protein in a mechanically stable nanostructured format that has been broadly characterized, showing promising potential in different fields such as tissue engineering, protein replacement therapies, cancer, and biotechnology. For immunomodulatory purposes, however, the interference of the format immunogenic properties-intrinsic to IBs-with the specific effects of the therapeutic protein is still an uncovered gap. For that, active and inactive forms of the catalytic domain of a matrix metalloproteinase-9 (MMP-9 and mutMMP-9, respectively) have been produced as IBs and compared with the soluble form for dermal inflammatory effects in mmp9 knock-out mice. After protein injections in air-pouches in the mouse model, MMP-9 IBs induce local neutrophil recruitment and increase pro-inflammatory chemokine levels, lasting for at least two days, whereas the effects triggered by the soluble MMP-9 format fade out after 3 h. Interestingly, the IB intrinsic effects (mutMMP-9 IBs) do not last more than 24 h. Therefore, it may be concluded that IBs could be used for the delivery of therapeutic proteins, such as immunomodulating proteins while preserving their stability in the specific tissue and without triggering important unspecific inflammatory responses due to the protein format.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The biological potential hidden in inclusion bodies

  • Gifre-Renom, Laia|||0000-0002-2115-2033
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Rafael, Diana|||0000-0003-3180-3028
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Martinez-Trucharte, Francesc|||0000-0001-8056-5623
  • Ugarte-Berzal, Estefanía
  • Martens, Erik|||0000-0002-7947-6567
  • Boon, Lise
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Opdenakker, Ghislain
  • Schwartz, Simon|||0000-0001-8297-7971
  • Arís i Giralt, Anna|||0000-0001-7830-888X
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
Inclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. Nevertheless, IBs have been, so far, exclusively sifted by their biological activity in vitro to be considered in further protein-based treatments in vivo. Matrix metalloproteinase-9 (MMP-9) protein, which has an important role facilitating the migration of immune cells, was used as model protein. The MMP-9 IBs were compared with their soluble counterpart and with MMP-9 encapsulated in polymeric-based micelles (PM) through ionic and covalent binding. The soluble MMP-9 and the MMP-9-ionic PM showed the highest activity values in vitro. IBs showed the lowest activity values in vitro, but the specific activity evolution in 50% bovine serum at room temperature proved that they were the most stable format. The data obtained with the use of an air-pouch mouse model showed that MMP-9 IBs presented the highest in vivo activity compared to the soluble MMP-9, which was associated only to a low and a transitory peak of activity. These results demonstrated that the in vivo performance is the addition of many parameters that did not always correlate with the in vitro behavior of the protein of interest, becoming especially relevant at evaluating the potential of IBs as a protein-based nanomaterial for therapeutic purposes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomic and biotechnological insights on stress-linked polyphosphate production induced by chromium(III) in Ochrobactrum anthropi DE2010

  • Villagrasa, Eduard|||0000-0003-1846-4244
  • Egea, Raquel|||0000-0002-6201-4112
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Solé Cornellà, Antoni|||0000-0002-1151-319X
The resistance of microorganisms to heavy metals in polluted environments is mediated by genetically determined mechanisms. One such mechanism includes the intracellular sequestration of heavy metals in polyphosphate (polyP) inclusions. In Cr(III) contaminated mediums, Ochrobactrum anthropi DE2010 is able to bind and sequester Cr(III) in polyP inclusions. In order to further study the relationship between Cr(III) tolerance and polyP production in O. anthropi DE2010, we carried out whole genomic sequencing, analysis of single nucleotide polymorphisms (SNPs), polyP chemical quantification, and determination of the relative abundance and morphometry of polyP inclusions. In the O. anthropi DE2010 genome, six polyP and pyrophosphate (PPi) metabolic genes were found. Furthermore, genomic analysis via SNPs calling revealed that O. anthropi ATCC49188 and DE2010 strains had average variations of 1.51% in their whole genome sequences and 1.35% variation associated with the principal polyP metabolic gene cluster. In addition, the accumulation of polyP in the DE2010 strain and number of polyP inclusions found were directly correlated with the concentration of Cr(III) in contaminated cultures. The results presented in this study may enhance the understanding of polyP production in response to Cr(III) toxicity in the O. anthropi DE2010 strain. This knowledge may facilitate the successful removal of Cr(III) from the natural environment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Potential of MMP-9 based nanoparticles at optimizing the cow dry period, pulling apart the effects of MMP-9 and nanoparticles

  • Gifre-Renom, Laia|||0000-0002-2115-2033
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Parés Riera, Sílvia
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Bach, Àlex|||0000-0001-6804-2002
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
The cow dry period is a non-milking interval where the mammary gland involutes and regenerates to guarantee an optimal milk production in the subsequent lactation. Important bottlenecks such as the high risk of intramammary infections complicate the process. Antibiotics have been routinely used as a preventive treatment but the concerns about potential antibiotic resistance open a new scenario in which alternative strategies have to be developed. Matrix metalloproteinase-9 (MMP-9) is an enzyme able to degrade the extracellular matrix, triggering the involution and immune function of cow mammary gland. We have studied the infusion into the mammary gland of MMP-9 inclusion bodies as protein-based nanoparticles, demonstrating that 1.2 mg of MMP-9 enhanced the involution and immune function of the cow mammary gland. However, the comparison of the effects triggered by the administration of an active and an inactive form of MMP-9 led to conclude that the response observed in the bovine mammary gland was mainly due to the protein format but not to the biological activity of the MMP-9 embedded in the inclusion body. This study provides relevant information on the future use of protein inclusion bodies in cow mammary gland and the role of MMP-9 at dry-off.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improving biomaterials imaging for nanotechnology, rapid methods for protein localization at ultrastructural level

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
The preparation of biological samples for electron microscopy is material- and time-consuming because it is often based on long protocols that also may produce artifacts. Protein labeling for transmission electron microscopy (TEM) is such an example, taking several days. However, for protein-based nanotechnology, high resolution imaging techniques are unique and crucial tools for studying the spatial distribution of these molecules, either alone or as components of biomaterials. In this paper, we tested two new short methods of immunolocalization for TEM, and compared them with a standard protocol in qualitative and quantitative approaches by using four protein-based nanoparticles. We reported a significant increase of labeling per area of nanoparticle in both new methodologies (H = 19.811; p < 0.001) with all the model antigens tested: GFP (H = 22.115; p < 0.001), MMP-2 (H = 19.579; p < 0.001), MMP-9 (H = 7.567; p < 0.023), and IFN-γ (H = 62.110; p < 0.001). We also found that the most suitable protocol for labeling depends on the nanoparticle's tendency to aggregate. Moreover, the shorter methods reduce artifacts, time (by 30%), residues, and reagents hindering, losing, or altering antigens, and obtaining a significant increase of protein localization (of about 200%). Overall, this study makes a step forward in the development of optimized protocols for the nanoscale localization of peptides and proteins within new biomaterials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Intracellular trafficking of a dynein-based nanoparticle designed for gene delivery

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • De Cabo, Martí
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Azzoni, Adriano Rodrigues|||0000-0003-0696-4663
The success of viruses in the delivery of the viral genome to target cells relies on the evolutionary selection of protein-based domains able to hijack the intermolecular interactions through which cells respond to intra- and extracellular stimuli. In an effort to mimic viral infection capabilities during non-viral gene delivery, a modular recombinant protein named T-Rp3 was recently developed, containing a DNA binding domain, a dynein molecular motor interacting domain, and a TAT-derived transduction domain. Here, we analyzed at the microscopic level the mechanisms behind the cell internalization and intracellular trafficking of this highly efficient modular protein vector. We found that the protein has the ability to self-assemble in discrete protein nanoparticles resembling viral capsids, to bind and condense plasmid DNA (pDNA), and to interact with eukaryotic cell membranes. Confocal and single particle tracking assays performed on living HeLa cells revealed that the T-Rp3 nanoparticles promoted an impressive speed of cellular uptake and perinuclear accumulation. Finally, the protein demonstrated to be a versatile vector, delivering siRNA at efficiencies comparable to Lipofectamine™. These results demonstrate the high potential of recombinant modular proteins with merging biological functions to fulfill several requirements needed to obtain cost-effective non-viral vectors for gene-based therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The potential of metalloproteinase-9 administration to accelerate mammary involution and boost the immune system at dry-off

  • Parés Riera, Sílvia
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Bach, Àlex|||0000-0001-6804-2002
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
The dry period is decisive for the milking performance of dairy cows. The promptness of mammary gland involution at dry-off affects not only the productivity in the next lactation, but also the risk of new intra-mammary infections since it is closely related with the activity of the immune system. Matrix metalloproteinase-9 (MMP-9) is an enzyme present in the mammary gland and has an active role during involution by disrupting the extracellular matrix, mediating cell survival and the recruitment of immune cells. The objective of this study was to determine the potential of exogenous administration of a soluble and recombinant version of a truncated MMP-9 (rtMMP-9) to accelerate mammary involution and boost the immune system at dry-off, avoiding the use of antibiotics. Twelve Holstein cows were dried abruptly, and two quarters of each cow received an intra-mammary infusion of either soluble rtMMP-9 or a positive control based on immunostimulant inclusion bodies (IBs). The contralateral quarters were infused with saline solution as negative control. Samples of mammary secretion were collected during the week following dry-off to determine SCC, metalloproteinase activity, bovine serum albumin, lactoferrin, sodium, and potassium concentrations. The soluble form of rtMMP-9 increased endogenous metalloproteinase activity in the mammary gland compared with saline quarters but did not accelerate either the immune response or involution in comparison with control quarters. The results demonstrated that the strategy to increase the mammary gland immunocompetence by recombinant infusion of rtMMP-9 was unsuccessful.